Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 5
2003 3
2004 1
2005 1
2006 1
2008 2
2009 2
2010 1
2012 3
2013 3
2014 2
2015 1
2016 4
2017 3
2018 3
2021 1
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Hagenbeek TJ, Zbieg JR, Hafner M, Mroue R, Lacap JA, Sodir NM, Noland CL, Afghani S, Kishore A, Bhat KP, Yao X, Schmidt S, Clausen S, Steffek M, Lee W, Beroza P, Martin S, Lin E, Fong R, Di Lello P, Kubala MH, Yang MN, Lau JT, Chan E, Arrazate A, An L, Levy E, Lorenzo MN, Lee HJ, Pham TH, Modrusan Z, Zang R, Chen YC, Kabza M, Ahmed M, Li J, Chang MT, Maddalo D, Evangelista M, Ye X, Crawford JJ, Dey A. Hagenbeek TJ, et al. Among authors: evangelista m. Nat Cancer. 2023 Jun;4(6):812-828. doi: 10.1038/s43018-023-00577-0. Epub 2023 Jun 5. Nat Cancer. 2023. PMID: 37277530 Free PMC article.
Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase.
Wei B, Robarge K, Labadie SS, Chen J, Corson LB, DiPasquale A, Dragovich PS, Eigenbrot C, Evangelista M, Fauber BP, Hitz A, Hong R, Lai KW, Liu W, Ma S, Malek S, O'Brien T, Pang J, Peterson D, Salphati L, Sampath D, Sideris S, Ultsch M, Xu Z, Yen I, Yu D, Yue Q, Zhou A, Purkey HE. Wei B, et al. Among authors: evangelista m. Bioorg Med Chem Lett. 2022 Mar 1;59:128576. doi: 10.1016/j.bmcl.2022.128576. Epub 2022 Jan 19. Bioorg Med Chem Lett. 2022. PMID: 35065235
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors.
Davies CW, Oh AJ, Mroue R, Steffek M, Bruning JM, Xiao Y, Feng S, Jayakar S, Chan E, Arumugam V, Uribe SC, Drummond J, Frommlet A, Lu C, Franke Y, Merchant M, Koeppen H, Quinn JG, Malhotra S, Do S, Gazzard L, Purkey HE, Rudolph J, Mulvihill MM, Koerber JT, Wang W, Evangelista M. Davies CW, et al. Among authors: evangelista m. Nat Biotechnol. 2022 May;40(5):769-778. doi: 10.1038/s41587-021-01126-9. Epub 2022 Jan 6. Nat Biotechnol. 2022. PMID: 34992247
Identifying transcriptional programs underlying cancer drug response with TraCe-seq.
Chang MT, Shanahan F, Nguyen TTT, Staben ST, Gazzard L, Yamazoe S, Wertz IE, Piskol R, Yang YA, Modrusan Z, Haley B, Evangelista M, Malek S, Foster SA, Ye X. Chang MT, et al. Among authors: evangelista m. Nat Biotechnol. 2022 Jan;40(1):86-93. doi: 10.1038/s41587-021-01005-3. Epub 2021 Sep 16. Nat Biotechnol. 2022. PMID: 34531539
The hedgehog signaling pathway in cancer.
Evangelista M, Tian H, de Sauvage FJ. Evangelista M, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5924-8. doi: 10.1158/1078-0432.CCR-06-1736. Clin Cancer Res. 2006. PMID: 17062662 Review.
Structure-Based Design and Evaluation of Reversible KRAS G13D Inhibitors.
Nilewski C, Labadie S, Wei B, Malhotra S, Do S, Gazzard L, Liu L, Shao C, Murray J, Izrayelit Y, Gustafson A, Endres NF, Ma F, Ye X, Zou J, Evangelista M. Nilewski C, et al. Among authors: evangelista m. ACS Med Chem Lett. 2023 Dec 6;15(1):21-28. doi: 10.1021/acsmedchemlett.3c00478. eCollection 2024 Jan 11. ACS Med Chem Lett. 2023. PMID: 38229748 Free PMC article.
42 results